- \n
- Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry Eye Disease Expected in Fourth Quarter of 2021 <\/i><\/li>\n
- U.S. FDA Grants Orphan Drug Designation to ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma and Retinitis Pigmentosa<\/i><\/li>\n
- Initial Results from Phase 2 Clinical Trials of Oral RASP Inhibitor ADX-629 in Multiple Systemic Indications Anticipated in Fourth Quarter of 2021 or First Quarter of 2022 <\/i><\/li>\n
- Cash and Cash Equivalents of $249.7 Million as of June 30, 2021; Projected Cash Runway Through 2023, Including Potential New Drug Applications; Initial Commercialization of Reproxalap, if Approved; and Continued Development of Compounds for Retinal and Systemic Diseases <\/i><\/li>\n
- Management to Host Conference Call at 8:00 a.m. ET Today <\/i><\/li>\n<\/ul>\n
LEXINGTON, Mass.–(BUSINESS WIRE<\/a>)–Aldeyra Therapeutics, Inc.<\/a> (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended June 30, 2021 and recent corporate highlights.\n<\/p>\n
\n\u201cWe continue to make meaningful strides toward our goal of developing effective and highly differentiated new therapies to treat ocular and systemic diseases with significant unmet medical need,\u201d stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. \u201cWe remain on schedule to report top-line results from the Phase 3 TRANQUILITY and TRANQUILITY-2 dry eye disease clinical trials in the fourth quarter of this year, and we look forward to releasing results of our Phase 2 clinical trials of ADX-629 in systemic immunological diseases by the end of the year or early 2022.\u201d\n<\/p>\n
Recent Corporate Highlights and Program Updates<\/b><\/p>\n
- \n
- Phase 3 TRANQUILITY and TRANQUILITY-2 Dry Eye Disease Clinical Trial Results Expected in the Fourth Quarter of 2021: <\/b>Enrollment is ongoing in the dry eye chamber Phase 3 TRANQUILITY Trial of reproxalap. An identical trial, TRANQUILITY-2, is expected to begin enrollment this quarter. Ocular redness is the primary endpoint of the TRANQUILITY trials, which include tear RASP levels, Schirmer’s test, and dry-eye symptoms as secondary endpoints. Top-line results are expected in the fourth quarter of this year. In addition, the company has initiated a multi-center, double-masked, randomized, vehicle-controlled, parallel-group Phase 2 clinical trial of reproxalap in dry eye disease. The Phase 2 trial is designed to optimize the measurement of tear RASP levels, with approximately 75 patients expected to be enrolled per arm. Similar to TRANQUILITY, ocular redness is the primary endpoint in the trial.\n<\/li>\n
- Orphan Drug Designation Granted for ADX-2191 in Two Additional Retinal Disease Indications<\/b>:The U.S. Food and Drug Administration (FDA) granted orphan drug designation to ADX-2191 (methotrexate for intravitreal injection) for the treatment of two rare retinal diseases: primary vitreoretinal lymphoma, an aggressive, high-grade cancer; and retinitis pigmentosa (RP), a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Aldeyra plans to initiate a Phase 2 clinical trial of ADX-2191 in patients with RP this year. The FDA\u2019s orphan drug designation program is designed to provide financial incentives to sponsors for developing drugs and biologics for rare diseases and conditions, in part defined as affecting fewer than 200,000 people in the United States. Sponsors of designated orphan drugs are eligible for partial tax credits for clinical trial costs, waiver of the user fee for marketing applications and, upon approval, consideration for seven years of marketing exclusivity.\n<\/li>\n
- Phase 2 Clinical Trial Results from ADX-629, an Orally Available, Systems-Based RASP Inhibitor, Expected in the Fourth Quarter of 2021 or First Quarter of 2022: <\/b>Initial Phase 2 clinical trial results from ADX-629, a novel orally available RASP inhibitor currently undergoing testing in asthma, psoriasis, and COVID-19, are expected in the fourth quarter of 2021 or first quarter of 2022. ADX-629 represents a first-in-class systems-based therapeutic approach for the potential treatment of a myriad of immune-mediated diseases that today are treated with single-target drugs that can lead to serious toxicity.\n<\/li>\n<\/ul>\n
Second-Quarter 2021 Financial Results<\/b><\/p>\n
\nCash and cash equivalents as of June 30, 2021 were $249.7 million. Based on Aldeyra\u2019s current operating plan, the company believes that existing cash and cash equivalents will be sufficient to fund currently projected operating expenses through the end of 2023, including potential New Drug Application submissions for reproxalap; initial commercialization of reproxalap, if approved; and continued development of the company\u2019s product candidates in ocular and systemic immune-mediated diseases.\n<\/p>\n
\nFor the quarter ended June 30, 2021, Aldeyra reported a net loss of $14.9 million, compared with a net loss of $7.5 million for the quarter ended June 30, 2020. Net loss per share was $0.28 for the quarter ended June 30, 2021, compared with $0.25 for the same period in 2020. Losses have resulted from the costs of clinical trials and research and development programs, as well as from general and administrative expenses.\n<\/p>\n
\nResearch and development expenses were $11.5 million for the quarter ended June 30, 2021, compared with $4.9 million for the same period in 2020. The increase of $6.6 million is primarily related to the increase in clinical research and development expenditures.\n<\/p>\n
\nGeneral and administrative expenses were $3.1 million for the quarter ended June 30, 2021, compared with $2.2 million for the quarter ended June 30, 2020. The increase of $0.9 million is primarily due to an increase in personnel-related costs and other miscellaneous administrative expenses.\n<\/p>\n
\nFor the quarter ended June 30, 2021, total operating expenses were $14.5 million, compared with total operating expenses of $7.1 million for the same period in 2020.\n<\/p>\n
Conference Call & Webcast Information<\/b><\/p>\n
\nAldeyra will host a conference call at 8:00 a.m. ET today to discuss second-quarter 2021 financial results and recent corporate highlights. The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 4968588. Due to expected high demand, please dial in at least 15 minutes prior to the start time.\n<\/p>\n
\nA live webcast of the conference call will also be available on the Investor Relations page of the company\u2019s website at https:\/\/ir.aldeyra.com<\/a>. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.\n<\/p>\n
About Aldeyra Therapeutics, Inc.<\/i><\/b><\/p>\n
\nAldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the company\u2019s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company\u2019s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https:\/\/www.aldeyra.com\/<\/a> and follow us on LinkedIn<\/a>, Facebook<\/a>, and Twitter<\/a>.\n<\/p>\n
Safe Harbor Statement<\/i><\/b><\/p>\n
\nThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding submission of potential New Drug Applications; the anticipated timing of results from Aldeyra\u2019s clinical trials; and Aldeyra\u2019s projected cash runway. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “on track,” “scheduled,” “target,” “design,” “estimate,” “predict,” “potential,” “aim,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra’s development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, and other factors that could delay the initiation or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra’s clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; updated or refined data based on Aldeyra’s continuing review and quality control analysis of clinical data, Aldeyra’s ability to design clinical trials with protocols and endpoints acceptable to applicable regulatory authorities; delay in or failure to obtain regulatory approval of Aldeyra’s product candidates; the ability to maintain regulatory approval of Aldeyra’s product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Aldeyra’s product candidates in clinical trials focused on the same or on different indications; the risk that the results from smaller clinical trials or portions of clinical trials may not accurately predict results of larger scale trials or the remainder of a clinical trial; the scope, progress, expansion, and costs of developing and commercializing Aldeyra’s product candidates; uncertainty as to Aldeyra\u2019s ability to commercialize (alone or with others) Aldeyra’s product candidates following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra’s product candidates and the ability to serve those markets; Aldeyra’s expectations regarding Aldeyra’s expenses and revenue, the sufficiency or use of Aldeyra’s cash resources and needs for additional financing; political, economic, legal, social and health risks, including the recent COVID-19 outbreak and subsequent public health measures, that may affect Aldeyra\u2019s business or the global economy; the rate and degree of market acceptance of any of Aldeyra’s product candidates; Aldeyra’s expectations regarding competition; Aldeyra’s anticipated growth strategies; Aldeyra’s ability to attract or retain key personnel; Aldeyra\u2019s limited sales and marketing infrastructure; Aldeyra’s ability to establish and maintain development partnerships; Aldeyra\u2019s ability to successfully integrate acquisitions into its business; Aldeyra’s expectations regarding federal, state and foreign regulatory requirements; regulatory developments in the United States and foreign countries; Aldeyra’s ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra’s business and the market in which it operates; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Aldeyra’s Annual Report on Form 10-K for the year ended December 31, 2020, which is on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at https:\/\/www.sec.gov\/<\/a>. Additional factors may be described in those sections of Aldeyra’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, expected to be filed with the SEC in the third quarter of 2021.\n<\/p>\n
\nIn addition to the risks described above and in Aldeyra’s other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.\n<\/p>\n
\n
\n ALDEYRA THERAPEUTICS, INC.<\/b><\/td>\n<\/tr>\n \n CONSOLIDATED BALANCE SHEETS<\/b><\/td>\n<\/tr>\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n June 30,<\/b><\/td>\n \n December 31,<\/b><\/td>\n \n <\/tr>\n \n \n \n \n 2021<\/b><\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n 2020<\/b><\/p>\n<\/td>\n
\n <\/tr>\n \n ASSETS<\/b><\/td>\n \n (Unaudited)<\/b><\/td>\n \n \n \n <\/tr>\n \n Current assets:<\/td>\n \n \n \n \n \n <\/tr>\n \n Cash and cash equivalents<\/td>\n \n \n \n$ 124,739,010\n<\/p>\n<\/td>\n
\n \n \n$ 52,858,311\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Cash equivalent – reverse repurchase agreements<\/td>\n \n \n \n125,000,000\n<\/p>\n<\/td>\n
\n \n \n25,000,000\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Prepaid expenses and other current assets<\/td>\n \n \n \n6,521,718\n<\/p>\n<\/td>\n
\n \n \n5,200,957\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Total current assets<\/td>\n \n \n \n256,260,728\n<\/p>\n<\/td>\n
\n \n \n83,059,268\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Right-of-use assets<\/td>\n \n \n \n118,401\n<\/p>\n<\/td>\n
\n \n \n233,310\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Fixed assets, net<\/td>\n \n \n \n48,083\n<\/p>\n<\/td>\n
\n \n \n59,925\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Total assets<\/td>\n \n \n \n$ 256,427,212\n<\/p>\n<\/td>\n
\n \n \n$ 83,352,503\n<\/p>\n<\/td>\n
\n <\/tr>\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n LIABILITIES AND STOCKHOLDERS’ EQUITY<\/b><\/td>\n \n \n \n \n \n <\/tr>\n \n Current liabilities:<\/td>\n \n \n \n \n \n <\/tr>\n \n Accounts payable<\/td>\n \n \n \n$ 1,094,461\n<\/p>\n<\/td>\n
\n \n \n$ 381,638\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Accrued expenses<\/td>\n \n \n \n6,196,300\n<\/p>\n<\/td>\n
\n \n \n8,134,765\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Current portion of credit facility<\/td>\n \n \n \n\u2014\n<\/p>\n<\/td>\n
\n \n \n3,659,776\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Current portion of operating lease liabilities<\/td>\n \n \n \n118,401\n<\/p>\n<\/td>\n
\n \n \n233,310\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Total current liabilities<\/td>\n \n \n \n7,409,162\n<\/p>\n<\/td>\n
\n \n \n12,409,489\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Long-term debt<\/td>\n \n \n \n15,338,105\n<\/p>\n<\/td>\n
\n \n \n11,434,456\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Total liabilities<\/td>\n \n \n \n22,747,267\n<\/p>\n<\/td>\n
\n \n \n23,843,945\n<\/p>\n<\/td>\n
\n <\/tr>\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Commitments and contingencies<\/td>\n \n \n \n \n \n <\/tr>\n \n Stockholders’ equity:<\/td>\n \n \n \n \n \n <\/tr>\n \n Common stock, voting, $0.001 par value; 150,000,000 authorized
and 57,997,345 and 38,667,491 shares issued and outstanding, respectively<\/td>\n\n \n \n57,997\n<\/p>\n<\/td>\n
\n \n \n38,667\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Additional paid-in capital<\/td>\n \n \n \n496,764,448\n<\/p>\n<\/td>\n
\n \n \n296,385,619\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Accumulated deficit<\/td>\n \n \n \n(263,142,500)\n<\/p>\n<\/td>\n
\n \n \n(236,915,728)\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Total stockholders\u2019 equity<\/td>\n \n \n \n233,679,945\n<\/p>\n<\/td>\n
\n \n \n59,508,558\n<\/p>\n<\/td>\n
\n <\/tr>\n \n Total liabilities and stockholders\u2019 equity<\/td>\n \n \n \n$ 256,427,212\n<\/p>\n<\/td>\n
\n \n \n$ 83,352,503\n<\/p>\n<\/td>\n
\n <\/tr>\n<\/table>\n \n
\n ALDEYRA THERAPEUTICS, INC.<\/b><\/td>\n<\/tr>\n \n CONSOLIDATED STATEMENTS OF OPERATIONS<\/b><\/td>\n<\/tr>\n \n (UNAUDITED)<\/b><\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n Three Months Ended June 30,<\/b><\/td>\n \n \n Six Months Ended June 30,<\/b><\/td>\n<\/tr>\n \n \n \n \n 2021<\/b><\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n 2020<\/b><\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n 2021<\/b><\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n 2020<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Operating expenses:<\/td>\n \n \n \n \n \n \n \n \n <\/tr>\n \n Research and development<\/td>\n \n \n \n$ 11,474,446\n<\/p>\n<\/td>\n
\n \n \n$ 4,885,875\n<\/p>\n<\/td>\n
\n \n \n \n$ 19,200,788\n<\/p>\n<\/td>\n
\n \n \n$ 11,519,478\n<\/p>\n<\/td>\n<\/tr>\n
\n General and administrative<\/td>\n \n \n \n3,068,652\n<\/p>\n<\/td>\n
\n \n \n2,220,003\n<\/p>\n<\/td>\n
\n \n \n \n6,173,355\n<\/p>\n<\/td>\n
\n \n \n5,224,844\n<\/p>\n<\/td>\n<\/tr>\n
\n Loss from operations<\/td>\n \n \n \n(14,543,098)\n<\/p>\n<\/td>\n
\n \n \n(7,105,878)\n<\/p>\n<\/td>\n
\n \n \n \n(25,374,143)\n<\/p>\n<\/td>\n
\n \n \n(16,744,322)\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Other income (expense):<\/td>\n \n \n \n \n \n \n \n \n <\/tr>\n \n Interest income<\/td>\n \n \n \n39,665\n<\/p>\n<\/td>\n
\n \n \n71,710\n<\/p>\n<\/td>\n
\n \n \n \n63,427\n<\/p>\n<\/td>\n
\n \n \n281,809\n<\/p>\n<\/td>\n<\/tr>\n
\n Interest expense<\/td>\n \n \n \n(433,477)\n<\/p>\n<\/td>\n
\n \n \n(486,048)\n<\/p>\n<\/td>\n
\n \n \n \n(916,056)\n<\/p>\n<\/td>\n
\n \n \n(925,863)\n<\/p>\n<\/td>\n<\/tr>\n
\n Total other income (expense), net<\/td>\n \n \n \n(393,812)\n<\/p>\n<\/td>\n
\n \n \n(414,338)\n<\/p>\n<\/td>\n
\n \n \n \n(852,629)\n<\/p>\n<\/td>\n
\n \n \n(644,054)\n<\/p>\n<\/td>\n<\/tr>\n
\n Net loss<\/td>\n \n \n \n$ (14,936,910)\n<\/p>\n<\/td>\n
\n \n \n$ (7,520,216)\n<\/p>\n<\/td>\n
\n \n \n \n$ (26,226,772)\n<\/p>\n<\/td>\n
\n \n \n$ (17,388,376)\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Net loss per share – basic and diluted<\/td>\n \n \n \n$ (0.28)\n<\/p>\n<\/td>\n
\n \n \n$ (0.25)\n<\/p>\n<\/td>\n
\n \n \n \n$ (0.52)\n<\/p>\n<\/td>\n
\n \n \n$ (0.59)\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Weighted average common shares outstanding – basic and diluted<\/td>\n \n \n \n54,280,393\n<\/p>\n<\/td>\n
\n \n \n30,118,456\n<\/p>\n<\/td>\n
\n \n \n \n49,979,545\n<\/p>\n<\/td>\n
\n \n \n29,586,148\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n\u00a0\n<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210805005246\/en\/<\/a><\/span><\/p>\n
Corporate Contact:
\n
<\/b>Joshua Reed
\n
Aldeyra Therapeutics, Inc.
\n
Tel: 781-761-4904 ext. 218
\n
jreed@aldeyra.com
\n<\/a><\/p>\nInvestor & Media Contact:
\n<\/b>
Scott Solomon
\n
Sharon Merrill Associates, Inc.
\n
Tel: 857-383-2409
\n
ALDX@investorrelations.com<\/a><\/p>\nKEYWORDS:<\/b> United States North America Massachusetts<\/p>\n
INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Optical Health FDA Clinical Trials<\/p>\n
- Orphan Drug Designation Granted for ADX-2191 in Two Additional Retinal Disease Indications<\/b>:The U.S. Food and Drug Administration (FDA) granted orphan drug designation to ADX-2191 (methotrexate for intravitreal injection) for the treatment of two rare retinal diseases: primary vitreoretinal lymphoma, an aggressive, high-grade cancer; and retinitis pigmentosa (RP), a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Aldeyra plans to initiate a Phase 2 clinical trial of ADX-2191 in patients with RP this year. The FDA\u2019s orphan drug designation program is designed to provide financial incentives to sponsors for developing drugs and biologics for rare diseases and conditions, in part defined as affecting fewer than 200,000 people in the United States. Sponsors of designated orphan drugs are eligible for partial tax credits for clinical trial costs, waiver of the user fee for marketing applications and, upon approval, consideration for seven years of marketing exclusivity.\n<\/li>\n
- U.S. FDA Grants Orphan Drug Designation to ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma and Retinitis Pigmentosa<\/i><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210805005246\/en\/896567\/3\/ALDX_logo_JPEG.jpg\"){kind=logo}
<\/td>\n<\/tr>\n